Core Viewpoint - Propanc Biopharma, Inc. has established a multi-year Joint Research Collaboration Agreement with the Universities of Jaén and Granada, marking the fifth agreement over a 17-year period, aimed at advancing research in chronic diseases, particularly cancer [1][2]. Group 1: Collaboration Details - The collaboration focuses on evaluating a senescence-modulating compound to mitigate aging effects and support claims related to recently filed patent applications concerning fibrosis and cancer [2]. - Prof. Macarena Perán Quesada from the University of Jaén will manage the project, with two postdoctoral fellows conducting in vitro and in vivo experiments [2][3]. Group 2: Project Goals and Market Potential - The company aims to advance its lead asset, PRP, to a Phase 1b, First-In-Human study in advanced cancer patients within the year, while strengthening its intellectual property [4]. - The market potential for PRP is significant, with expectations of broadening its therapeutic applications in life-threatening diseases through cell and tissue rejuvenation [4][5].